These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 11766999)

  • 1. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline.
    Pezzella G; Moslinger-Gehmayr R; Contu A
    Breast Cancer Res Treat; 2001 Nov; 70(1):1-10. PubMed ID: 11766999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, multicentre study to assess the tolerability and efficacy of paroxetine compared with amitriptyline in the treatment of depressed patients in Australian general practice.
    Freed E; Goldney R; Lambert T; Tiller J; Johnston R
    Aust N Z J Psychiatry; 1999 Jun; 33(3):416-21. PubMed ID: 10442799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression].
    Möslinger-Gehmayr R; Zaninelli R; Contu A; Oberhoff C; Gutschow K; Schindler AE; Staab HJ
    Zentralbl Gynakol; 2000; 122(4):195-202. PubMed ID: 10795116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
    Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB
    J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative efficacy and tolerability of paroxetine and amitriptiline in long-term therapy preventing depressive recurrences].
    Mosolov SN; Kostiukova EG; Gorodnichev AV; Timofeev IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(10):22-9. PubMed ID: 16281375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study.
    Bird H; Broggini M
    J Rheumatol; 2000 Dec; 27(12):2791-7. PubMed ID: 11128665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tolerance of venlafaxine, paroxetine and amitriptyline in depression therapy.
    Miskovic M
    Med Arch; 2015 Apr; 69(2):107-9. PubMed ID: 26005260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine.
    Chiu HJ; Hong CJ; Chan CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Jun; 57(6):418-23. PubMed ID: 8803304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression.
    Lydiard RB; Stahl SM; Hertzman M; Harrison WM
    J Clin Psychiatry; 1997 Nov; 58(11):484-91. PubMed ID: 9413414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial.
    Braconnier A; Le Coent R; Cohen D;
    J Am Acad Child Adolesc Psychiatry; 2003 Jan; 42(1):22-9. PubMed ID: 12500073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on paroxetine in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine and amitriptyline in the treatment of depression in general practice.
    Christiansen PE; Behnke K; Black CH; Ohrström JK; Bork-Rasmussen H; Nilsson J
    Acta Psychiatr Scand; 1996 Mar; 93(3):158-63. PubMed ID: 8739658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease.
    Pollok J; van Agteren JE; Carson-Chahhoud KV
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012346. PubMed ID: 30566235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amitriptyline for depression.
    Guaiana G; Barbui C; Hotopf M
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004186. PubMed ID: 17636748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients.
    Stuppaeck CH; Geretsegger C; Whitworth AB; Schubert H; Platz T; König P; Hinterhuber H; Fleischhacker WW
    J Clin Psychopharmacol; 1994 Aug; 14(4):241-6. PubMed ID: 7962679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased concentration of corticosteroid-binding globulin due to antidepressant treatment with amitritpyline, but not paroxetine.
    Deuschle M; Luppa P; Hamann B; Nonell A; Heuser I
    J Psychiatr Res; 2003; 37(1):85-7. PubMed ID: 12482473
    [No Abstract]   [Full Text] [Related]  

  • 18. Amitriptyline versus other types of pharmacotherapy for depression.
    Guaiana G; Barbui C; Hotopf M
    Cochrane Database Syst Rev; 2003; (2):CD004186. PubMed ID: 12804503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical effectiveness and safety of paroxetine in post-stroke depression: results from a phase 4, open label, multicenter clinical trial with 26 weeks of follow-up].
    Horváth S; Karányi Z; Harcos P; Nagy Z; Németh G; Andor G
    Orv Hetil; 2006 Dec; 147(50):2397-404. PubMed ID: 17274185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.